Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 32 (66.7%)
Phase 41 (33.3%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_3

Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

NCT05175131
completedphase_4

Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

NCT00934973
recruitingphase_3

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

NCT04217733
completed

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

NCT02260154

Clinical Trials (4)

Showing 4 of 4 trials
NCT05175131Phase 3

Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

Completed
NCT00934973Phase 4

Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

Completed
NCT04217733Phase 3

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Recruiting
NCT02260154

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4